

Nitric Oxide

Contributors

J.-L. Balligand, T.R. Billiar, C. Bogdan, B. Brüne, H. Bult,
V. Burkart, R. Busse, A. Costa, T.M. Dawson, V.L. Dawson,
V.J. Dzau, M.G. Espey, K. Falke, M. Feelisch, I. Fleming,
U. Förstermann, A. Friebe, J. Fukuto, J. Garthwaite, H. Gerlach,
S. Ghosh, M.B. Grisham, A.B. Grossman, E. Hackenthal,
D. Keh, M.M. Kockx, D. Koesling, G. Kojda, H. Kolb,
P.A. MacCarthy, W. Martin, K.E. Matthys, L. McNaughton,
K.M. Miranda, J.B. Mitchell, S. Moncada, P. Navarra,
J. Parkinson, A. Radomski, M.W. Radomski, D. Rees,
K. Sandau, M. Sasaki, G. Sawicki, H.H.H.W. Schmidt,
A.M. Shah, D.J. Stuehr, P. Vallance, H.E. von der Leyen,
A. von Knethen, E.R. Werner, D.A. Wink, R. Zamora

Editor

B. Mayer



Springer

Contents

Introduction

| | |
|------------------|---|
| S. MONCADA | 1 |
|------------------|---|

Section I: Chemistry

CHAPTER 1

The Chemical Biology of Nitric Oxide. Balancing Nitric Oxide with Oxidative and Nitrosative Stress

| | |
|---|----|
| D.A. WINK, K.M. MIRANDA, M.G. ESPEY, J.B. MITCHELL, M.B. GRISHAM, J. FUKUTO, and M. FEELISCH. With 8 Figures | 7 |
| A. Introduction | 7 |
| B. Direct Effects | 9 |
| I. Reactions Between NO and Metal Complexes | 9 |
| II. Interaction of NO with Metal–Oxygen and Metal–Oxo Complexes | 11 |
| III. The Reaction of NO with Radical Species | 13 |
| C. Indirect Effects | 14 |
| D. Nitrosative Stress | 15 |
| E. Oxidative Stress | 18 |
| F. NO/O ₂ ^{•−} Chemistry | 21 |
| G. Conclusion | 23 |
| References | 24 |

Section II: Biochemistry and Pharmacology of NO Synthesis and Action

CHAPTER 2

Enzymology of Nitric Oxide Synthases

| | |
|---|----|
| D.J. STUEHR and S. GHOSH. With 14 Figures | 33 |
| A. Introduction | 33 |
| B. NOS Structure–Function | 33 |
| I. Domain Organization | 33 |

| | |
|---|----|
| II. NOS Oxygenase Domains and Mutagenesis | 35 |
| 1. Arg-Binding Site | 36 |
| 2. H ₄ biopterin-Binding Site | 38 |
| 3. N-Terminal Hairpin Loop | 41 |
| 4. NOS Cysteines and Metal Binding | 42 |
| III. NOS Reductase Domains | 43 |
| 1. General Features | 43 |
| 2. Catalytic Properties and Response to CaM | 44 |
| 3. Mutagenesis | 45 |
| IV. CaM Activation of NOS | 47 |
| 1. Mechanism of Action | 47 |
| 2. Structural Determinants of CaM Binding | 47 |
| V. NOS Domain Interactions | 48 |
| C. Catalysis of NO Synthesis from L-Arg | 49 |
| I. Heme-NO Complex Formation | 49 |
| 1. NOS Partitioning into an NO-Bound Form During Catalysis | 49 |
| 2. Impact of NO Complex Formation on NOS Catalysis | 49 |
| 3. The NO Complex and NOS O ₂ Response | 50 |
| II. The Active Catalytic Cycle | 51 |
| 1. Steps involved, O ₂ , Binding and Activation | 51 |
| 2. NOS Heme Iron Reduction | 52 |
| 3. Control of Heme Reduction by H ₄ B and Arg | 53 |
| III. Enzyme Structural Features that may Impact on NO Synthesis | 54 |
| IV. Roles for Heme and H ₄ B | 56 |
| D. Control Mechanisms and Targeting | 58 |
| I. NOS Dimerization | 58 |
| 1. Stepwise Assembly Mechanism | 58 |
| 2. Positive and Negative Regulation | 59 |
| II. Is NOS Oxygenase Domain Structure Modified by Dimerization, H ₄ B Binding, or Both? | 59 |
| III. Another Type of NO Inhibition | 60 |
| IV. Interactions Between NOS and Other Proteins | 60 |
| 1. PDZ, PIN | 60 |
| 2. Caveolins | 61 |
| 3. Heat Shock Proteins | 62 |
| 4. Kalirin | 62 |
| References | 62 |

CHAPTER 3

Regulation of Nitric Oxide Synthase Expression and Activity

| | |
|----------------------|----|
| U. FÖRSTERMANN | 71 |
|----------------------|----|

| | |
|--|----|
| A. Introduction | 71 |
| B. Nitric Oxide Synthase I | 73 |
| I. Cellular Expression of NOS-I | 73 |
| II. Regulation of NOS-I Expression | 73 |
| III. Regulation of NOS-I Activity | 74 |
| C. Nitric Oxide Synthase II | 75 |
| I. Cellular Expression of NOS-II | 75 |
| II. Regulation of NOS-II Expression | 75 |
| III. Regulation of NOS-II Activity | 78 |
| D. Nitric Oxide Synthase III | 79 |
| I. Cellular Expression of NOS-III | 79 |
| II. Regulation of NOS-III Expression | 79 |
| III. Regulation of NOS-III Activity | 81 |
| E. Summary and Conclusions | 82 |
| References | 83 |

CHAPTER 4

Enzymology of Soluble Guanylyl Cyclase

| | |
|---|-----|
| D. KOESLING and A. FRIEBE. With 4 Figures | 93 |
| A. Introduction | 93 |
| B. Regulation of sGC | 94 |
| I. NO, the Physiological Activator of sGC | 94 |
| II. Mechanism of Activation of sGC by NO | 96 |
| III. Termination of the NO-Induced Activation | 96 |
| IV. CO: a Physiological Activator of sGC? | 98 |
| V. Redox Regulation of sGC? | 98 |
| VI. Modulators of sGC | 99 |
| 1. ODQ: An Inhibitor of the Stimulated Activity of sGC | 99 |
| 2. YC-1: A Novel Activator of sGC | 99 |
| C. Structure of sGC | 101 |
| I. Isoforms and Tissue Distribution | 101 |
| II. Primary Structure and Homology among the Subunits of sGC | 102 |
| III. The Regulatory Heme-Binding Domain | 102 |
| IV. Catalytic Domain | 103 |
| D. Conclusions | 105 |
| References | 105 |

CHAPTER 5

Nitric Oxide Synthase Inhibitors I: Substrate Analogs and Heme Ligands

| | |
|--------------------------------------|-----|
| J.F. PARKINSON. With 4 Figures | 111 |
|--------------------------------------|-----|

| | |
|--|-----|
| A. Introduction | 111 |
| I. Therapeutic Concepts for NOS Inhibitors | 111 |
| II. NOS-Knockout Mice | 112 |
| B. Mechanism-Based NOS Inhibitors | 114 |
| I. Substrate-Based NOS Inhibitors | 114 |
| 1. Arginine Analogs | 114 |
| 2. Amidine-Containing Inhibitors | 119 |
| 3. Summary for Substrate Analogs | 124 |
| II. Heme Ligands | 124 |
| 1. Summary for Heme Ligands | 127 |
| III. Towards Rational Design of NOS Inhibitors | 127 |
| References | 129 |

CHAPTER 6

Nitric-Oxide-Synthase Inhibitors II – Pterin Antagonists/ Anti-Pterins

| | |
|--|-----|
| E.R. WERNER and H.H.H.W. SCHMIDT. With 6 Figures | 137 |
| A. Introduction | 137 |
| B. H ₄ B Dependence of the NOS Reaction | 137 |
| I. NOS-Associated H ₄ B | 138 |
| II. Allosteric and Stabilising Effects | 138 |
| III. Possible Electron-Transfer Role | 138 |
| IV. The Pterin-Binding Site | 140 |
| C. Pterin-Based Inhibition OF NOS | 140 |
| I. Manipulating Intracellular H ₄ B Levels | 140 |
| II. Approaches to Pterin Antagonists | 141 |
| III. 4-Amino-H ₄ B | 142 |
| 1. Effects of 4-Amino-H ₄ B on Purified Enzymes | 142 |
| 2. Effects of 4-Amino-H ₄ B on Cultured Cells | 144 |
| 3. Effects of 4-Amino-H ₄ B in Animals | 144 |
| IV. Further 4-Aminopteridines | 145 |
| 1. The 4-Amino Function | 145 |
| 2. The 2, 5 and 7 Positions | 145 |
| 3. The C6 Side Chain and Pterin Exosite | 147 |
| 4. Conclusion | 149 |
| V. 4-Oxopteridines as Inhibitors of NOS | 149 |
| 1. Specificity and the Anti-Pterin-Binding Domain | 151 |
| 2. Type-I and -II Anti-Pterins | 151 |
| 3. 4-Oxo Anti-Pterins in Intact Cells | 153 |
| 4. Conclusions | 153 |
| D. Outlook | 154 |
| References | 155 |

CHAPTER 7

Mechanisms of Cellular Resistance Against Nitric Oxide

B. BRÜNE, ANDREAS VON KNETHEN, and K. SANDAU.

| | |
|---|-----|
| With 3 Figures | 159 |
| A. Introduction | 159 |
| I. Cell Death: Apoptosis Versus Necrosis | 159 |
| II. NO: Formation and Signaling | 161 |
| B. Cytotoxicity of Nitric Oxide | 161 |
| I. NO-Mediated Cytotoxicity/Apoptosis | 161 |
| II. Apoptotic-Signal Transduction: p53 Accumulation and Caspase Activation | 162 |
| C. Resistance Against NO [•] -Mediated Toxicity | 164 |
| I. Antagonism by Bcl-2-Family Members | 164 |
| II. Protection by NO [•] and O ₂ ⁻ Co-Generation | 164 |
| III. Protective Protein Expression | 166 |
| IV. cGMP Formation and Protein Thiol Modification | 167 |
| D. Conclusions | 169 |
| References | 171 |

Section III: Physiological Functions of NO

CHAPTER 8

Nitric Oxide and Regulation of Vascular Tone

| | |
|---|-----|
| R. BUSSE and I. FLEMING. With 3 Figures | 179 |
| A. Regulation of Vascular Tone | 179 |
| B. Endothelial Nitric Oxide Synthase | 180 |
| I. Ca ²⁺ -Dependent eNOS Activation | 181 |
| 1. The Interaction of eNOS with CaM | 181 |
| 2. The Interaction of eNOS with Caveolin-1 | 182 |
| 3. Other Modulators of eNOS Activity | 183 |
| a) Endothelial NOS-Associated Protein-1 | 183 |
| b) Hsp90 | 183 |
| c) Phosphorylation | 184 |
| II. Ca ²⁺ -Independent eNOS Activation | 185 |
| III. The Link Between Fluid Shear Stress and NO Production | 186 |
| C. Mechanisms of Action of NO on Vascular Smooth Muscle | 187 |
| I. Effects of NO on [Ca ²⁺] _i | 187 |
| II. Effects of NO on Cyclic Nucleotide Phosphodiesterase III | 189 |

| | |
|---|-----|
| III. Effects of NO on Other Systems Involved in the Control of Vascular Tone | 190 |
| 1. Endothelin-1 | 190 |
| 2. Noradrenaline | 190 |
| 3. NO and Iron-Containing Proteins | 191 |
| 4. NO and Mitochondrial Respiration | 191 |
| IV. Dinitrosyl Iron Complexes, Nitrosothiol-Containing Proteins and Vascular Tone | 192 |
| D. NO and the Control of Blood Flow | 193 |
| I. Interaction between NO and O_2^- | 195 |
| II. NO and 20-HETE | 197 |
| References | 198 |

CHAPTER 9

Regulation of Cardiac Function by Nitric Oxide

| | |
|---|-----|
| J.-L. BALLIGAND. With 1 Figure | 207 |
| A. Introduction | 207 |
| B. Specifics on Cardiac NOS Biology | 207 |
| I. Which Isoform(s)? | 207 |
| II. How are they Regulated? | 209 |
| 1. Endothelial Nitric Oxide Synthase | 209 |
| a) Expressional Control | 209 |
| b) Acute Regulation of Activity | 210 |
| α . Mechanical Forces | 210 |
| β . Beating Rate | 210 |
| γ . β -Adrenergic Agonists | 211 |
| δ . Muscarinic Cholinergic Agonists | 211 |
| ϵ . Acute Effect of Cytokines | 212 |
| 2. Inducible Nitric Oxide Synthase | 213 |
| a) Expressional Control | 213 |
| b) Acute Regulation of Activity | 213 |
| C. Intracellular Mechanisms of Action of NO in Cardiac Muscle Cells | 214 |
| I. Cyclic GMP-Dependent Mechanisms | 214 |
| 1. Contraction-Enhancing Mechanisms | 214 |
| 2. Contraction-Decreasing Mechanisms | 217 |
| II. Cyclic GMP-Independent Mechanisms | 218 |
| 1. Contraction-Enhancing Mechanisms | 218 |
| 2. Contraction-Decreasing Mechanisms | 218 |
| D. Regulation of Cardiac Function by eNOS | 219 |
| I. Basal Systolic and Diastolic Function | 219 |
| II. Regulation of β -Adrenergic Response | 220 |
| III. Regulation of Muscarinic Cholinergic Response | 221 |

| | |
|--|-----|
| E. Regulation of Cardiac Function by iNOS | 222 |
| I. Basal Contractile Function | 223 |
| II. Regulation of β -Adrenergic Response | 224 |
| III. iNOS and Cardiomyocyte Biology | 224 |
| F. Conclusion and Perspectives | 225 |
| References | 226 |

CHAPTER 10

Regulation of Platelet Function

L. McNAUGHTON, A. RADOMSKI, G. SAWICKI,

and M.W. RADOMSKI

235

| | |
|--|-----|
| A. Introduction | 235 |
| I. Platelet Rheology | 235 |
| II. Platelet Control | 235 |
| B. Nitric Oxide | 236 |
| I. NO in Platelets: the Quest | 236 |
| II. Molecular Biology of Platelet NOS | 236 |
| III. Regulation of NO Generation in Platelet Microenvironment | 237 |
| 1. Cell Activation | 237 |
| 2. Role of Substrate | 238 |
| 3. Role of Co-Factors | 238 |
| 4. Rheology | 238 |
| IV. Physiological Effects of NO on Platelets | 238 |
| 1. Effects of NO on Platelet Function In Vitro | 238 |
| 2. Effects of NO on Platelet Function In Vivo | 239 |
| 3. NO in Synergistic Regulation of Platelet Function | 239 |
| V. The Mechanisms of NO Action on Platelets | 239 |
| C. The Role of NO in the Pathogenesis of Vascular Disorders Associated with Platelet Activation | 241 |
| I. Pathomechanism | 241 |
| II. Atherosclerosis, Thrombosis and Hypertension | 242 |
| III. Diabetes Mellitus and Stress | 242 |
| IV. Pre-Eclampsia | 243 |
| V. Septicaemia | 243 |
| VI. Uraemia | 244 |
| VII. Cancer | 244 |
| D. Pharmacological Modulation of Formation and Action of NO on Platelets | 244 |
| I. L-Arginine | 244 |
| II. Stimulators of NOS | 245 |
| III. Inhibitors of NOS and NO Scavengers | 245 |
| IV. NO Gas | 246 |
| V. NO Donors | 246 |

| | |
|--|-----|
| VI. Novel NO Donors | 248 |
| VII. NO-Independent Activators of GC-S | 249 |
| E. Conclusions | 249 |
| References | 249 |

CHAPTER 11

The Physiological Roles of Nitric Oxide in the Central Nervous System

| | |
|--|-----|
| J. GARTHWAITE | 259 |
| A. Introduction | 259 |
| B. Acute Actions of NO | 261 |
| I. Synaptic Transmission | 261 |
| II. Gap Junctions | 263 |
| III. Local Cerebral Blood Flow | 264 |
| IV. Glial Cells | 265 |
| C. NO and Synaptic Plasticity | 266 |
| I. Short-Term Plasticity | 266 |
| II. Long-Term Potentiation | 267 |
| III. Long-Term Depression | 268 |
| D. NO and Developmental Plasticity | 268 |
| E. Concluding Remarks | 270 |
| References | 270 |

CHAPTER 12

The Role of Nitric Oxide in the Peripheral Nervous System

| | |
|---|-----|
| W. MARTIN | 277 |
| A. Introduction | 277 |
| I. Nomenclature | 277 |
| II. Historical Perspective | 277 |
| III. The Concept of Non-Adrenergic, Non-Cholinergic Neurotransmission | 278 |
| IV. The Concept of Nitrergic Nerves | 279 |
| B. Properties of Nitrergic Nerves | 281 |
| I. Properties of nNOS | 281 |
| II. Localisation of nNOS in Nitrergic Nerves | 281 |
| III. Anatomical Distribution and Physiological Functions of Nitrergic Nerves | 282 |
| IV. Unitary Transmission, Dual Transmission and Co-Transmission | 283 |
| C. Nature of the Nitrergic Neurotransmitter | 284 |
| I. Predicted Differences in the Effects of Drugs on Nerve-Derived and Bath-Applied NO | 285 |

| | |
|---|-----|
| II. Evidence that the Nitroergic Neurotransmitter is a NO-Like or NO-Releasing Molecule | 285 |
| III. Evidence that NO is the Nitroergic Neurotransmitter and is Protected from Inactivation | 287 |
| D. Pre-Junctional Mechanisms | 289 |
| I. Activation of Nitroergic Nerves | 289 |
| II. Role of Ca^{2+} in Activation of Nitroergic Nerves | 289 |
| III. Pre-Junctional Augmentation of Nitroergic Transmission | 290 |
| IV. Blockade of Nitroergic Transmission by Inhibition of NOS | 291 |
| E. Nerve–Nerve Interactions | 293 |
| I. Nitroergic–Adrenergic Interactions | 293 |
| II. Nitroergic–Cholinergic Interactions | 293 |
| III. Nitroergic–NANC Interactions | 294 |
| F. Junctional and Post-Junctional Mechanisms | 295 |
| I. Scavengers of NO | 295 |
| II. Blockade of Soluble Guanylate Cyclase | 295 |
| III. Post-Junctional Potentiation of Nitroergic Transmission | 296 |
| G. Post-Junctional Transduction Pathway | 297 |
| I. Role of Cyclic GMP | 297 |
| II. Inhibition of Calcium Mobilisation | 297 |
| III. Role of Membrane Hyperpolarisation | 298 |
| H. Concluding Remarks | 299 |
| References | 299 |

CHAPTER 13

Nitric Oxide and Neuroendocrine Function

| | |
|--|-----|
| P. NAVARRA, A. COSTA, and A. GROSSMAN. With 4 Figures | 315 |
| A. Introduction | 315 |
| B. NO Biosynthesis in the Hypothalamus: Relationship Between Localization and Function | 315 |
| C. Physiology of Hypothalamic NO | 317 |
| I. Vasopressin and Oxytocin | 317 |
| II. Corticotrophin-Releasing Hormone and the Hypothalamo–Pituitary–Adrenal Axis | 318 |
| III. Hypothalamo–Pituitary–Gonadal Axis | 320 |
| IV. Other Hormonal Systems | 322 |
| References | 323 |

CHAPTER 14

The Role of Nitric Oxide in Kidney Function

| | |
|---|-----|
| E. HACKENTHAL. With 6 Figures | 329 |
| A. Introduction | 329 |
| B. Nitric Oxide Synthase Isoforms in the Kidney | 329 |
| C. Distribution of NOS in the Kidney | 330 |
| I. Distribution of NOS in the Renal Vasculature | 330 |
| II. Distribution of NOS in Renal Tubules | 331 |
| III. Distribution of NOS in Renal Nerves | 333 |
| D. Physiological Roles of NO | 333 |
| I. Role of NO in the Regulation of Renal Blood Flow | 333 |
| 1. Endogenous Mediators of NO Release | 333 |
| 2. Inhibitors of NOS | 334 |
| II. Role of NO in Glomerular Circulation | 335 |
| III. Role of NO in Renal Autoregulation | 336 |
| 1. The Myogenic Response and NO | 338 |
| 2. NO and Tubuloglomerular Feedback | 338 |
| IV. Role of NO in the Control of Medullary Blood Flow and Pressure Natriuresis | 341 |
| E. Tubular Functions of NO | 342 |
| F. NO, Renin Secretion and Renin Synthesis | 343 |
| I. NO as a Stimulator of Renin Secretion | 344 |
| II. NO and Pressure Control of Renin Release | 344 |
| III. NO, Renal Nerves and Renin Release | 347 |
| IV. NO and Macula-Densa-Mediated Renin Secretion | 348 |
| V. NO, Prostaglandins and Renin Synthesis | 350 |
| G. Concluding Remarks | 352 |
| References | 353 |

Section IV: The Role of Pharmacological Action of NO in Human Disease

CHAPTER 15

Therapeutic Importance of Nitrovasodilators

| | |
|---|-----|
| G. KOJDA. With 3 Figures | 365 |
| A. Introduction | 365 |
| B. Mechanisms of Action | 367 |
| C. Hemodynamic Actions | 368 |
| I. Preferential Venodilation | 368 |
| II. Vessel-Size-Selective Coronary Vasodilation | 369 |
| III. Effects on Blood Pressure | 370 |
| IV. Other Effects on Hemodynamics | 371 |

| | |
|---|-----|
| V. Effects on Platelets | 371 |
| D. Pharmacokinetics | 372 |
| E. Clinical Use | 373 |
| I. Effects in Stable Angina | 373 |
| 1. Treatment and Short-Term Prevention of Anginal Attacks | 374 |
| 2. Long-Term Management of Chronic Stable Angina | 374 |
| II. Effects in Unstable Angina | 374 |
| III. Effects in Acute Myocardial Infarction | 375 |
| IV. Effects in Heart Failure | 375 |
| V. Effects in Gastrointestinal Disorders | 376 |
| VI. Effects on the Uterus | 376 |
| F. Nitrate Tolerance | 377 |
| G. Side Effects and Contraindications | 378 |
| References | 378 |

CHAPTER 16

Therapeutic Potential of NOS Inhibitors in Septic Shock

| | |
|--|-----|
| P. VALLANCE, D. REES, and S. MONCADA. With 5 Figures | 385 |
| A. Introduction | 385 |
| B. Clinical Features of Sepsis | 385 |
| I. Cardiovascular Changes | 386 |
| II. Tissue Oxygenation | 386 |
| III. Tissue and Organ Damage | 386 |
| C. NO in Experimental Models of Shock | 387 |
| I. Cardiovascular Changes | 388 |
| II. Tissue Oxygenation | 388 |
| III. Tissue and Organ Damage | 389 |
| D. NO in Clinical Sepsis | 390 |
| I. iNOS Induction in Humans | 391 |
| II. Cardiovascular Changes | 391 |
| III. Tissue Oxygenation | 393 |
| IV. Tissue and Organ Damage | 393 |
| E. Outcome Studies | 394 |
| F. Conclusions | 394 |
| References | 395 |

CHAPTER 17

Inhalation Therapy with Nitric Oxide Gas

| | |
|--|-----|
| D. KEH, H. GERLACH, and K. FALKE. With 7 Figures | 399 |
| A. Introduction | 399 |
| B. Therapy with NO Gas | 400 |

| | |
|---|-----|
| I. NO Inhalation in ARDS Patients | 400 |
| 1. Introduction | 400 |
| 2. Acute Effects of NO Inhalation in Patients with ARDS | 401 |
| 3. NO Inhalation and Non-Cardiogenic Pulmonary Edema | 404 |
| 4. Dose-Response Relationship of NO Inhalation | 404 |
| 5. Effects of NO Inhalation on Right Heart Function | 408 |
| 6. NO Non-Responders | 409 |
| 7. NO Dependency | 409 |
| 8. Recent Studies of NO Inhalation in ARDS | 410 |
| II. NO Inhalation in PPHN | 412 |
| III. NO Inhalation in Other Diseases | 414 |
| IV. NO Autoinhalation | 415 |
| C. NO Metabolism, Toxicology, and Adverse Effects | 417 |
| I. NO Uptake and Clearance | 417 |
| II. NO and Nitrogen Dioxide | 417 |
| III. NO, Superoxide, and Peroxynitrite | 419 |
| IV. NO and <i>S</i> -Nitrosothiols | 422 |
| 1. Methemoglobin | 422 |
| D. NO Administration | 424 |
| I. The NO/Nitrogen Gas Mixture | 424 |
| II. Delivery of NO | 425 |
| III. Monitoring of NO Inhalation | 429 |
| 1. Chemiluminescence | 429 |
| 2. Electrochemical Analyzers | 430 |
| References | 432 |

CHAPTER 18

The Function of Nitric Oxide in the Immune System

| | |
|--|-----|
| C. BOGDAN | 443 |
| A. Introduction | 443 |
| B. Type-2 NOS (NOS-II, iNOS) and the Immune System | 444 |
| I. Cell Types | 444 |
| II. Induction and Regulation | 444 |
| 1. Overview | 444 |
| 2. Transcriptional Regulation | 447 |
| 3. Positive and Negative Regulation of NOS-II by Cytokines, Ligand-Receptor Interactions, and Microbial Products | 449 |
| a) Cytokines | 449 |
| b) Cross-Linking of Cell-Surface Receptors | 451 |
| c) Microbial Products | 451 |

| | |
|--|-----|
| III. Functions | 453 |
| 1. Overview | 453 |
| 2. Antimicrobial Functions | 453 |
| a) Results from Host-Cell-Free Experiments and Studies in Rodents | 453 |
| b) NO as an Antimicrobial Molecule in Humans | 456 |
| c) Interaction Between NO and Other Antimicrobial Effector Pathways | 457 |
| 3. Anti-Tumor Function | 459 |
| 4. Autotoxic Functions | 460 |
| 5. Regulatory Functions | 461 |
| a) Regulation of Proliferation, Apoptosis and Survival, and Cytotoxic Activity of Lymphocytes | 462 |
| b) Modulation of Cytokine Responses | 463 |
| α . NO and IL-12 | 465 |
| c) Leukocyte Chemotaxis and Adhesion | 466 |
| d) Immune (T-Helper Cell) Deviation | 466 |
| C. Other NOS Isoforms and Perspective | 467 |
| References | 468 |

CHAPTER 19

Nitric Oxide: A True Inflammatory Mediator

| | |
|---|-----|
| R. ZAMORA and T.R. BILLIAR | 493 |
| A. Introduction | 493 |
| I. Biosynthesis of NO | 493 |
| B. NO and Inflammation | 494 |
| I. The Chemical Mediators of the Vascular Response | 495 |
| II. NO and the Vascular Response to Injury | 496 |
| III. NO in Acute Inflammatory Responses | 498 |
| IV. NO and Inflammatory Cytokines | 499 |
| V. NO and Arachidonic Acid Metabolites | 501 |
| C. NO in Immunity and Chronically Inflammatory Diseases | 502 |
| I. NO and the Immune Response | 502 |
| II. NO and Chronic Inflammatory Processes | 506 |
| III. Induced NO in Antimicrobial Defense Mechanisms | 508 |
| D. Conclusions | 510 |
| References | 511 |

CHAPTER 20

Nitric Oxide in the Immunopathogenesis of Type 1 Diabetes

| | |
|-------------------------------|-----|
| V. BURKART and H. KOILB | 525 |
| A. Introduction | 525 |

| | |
|---|-----|
| B. Type 1 Diabetes | 525 |
| I. Clinical Characteristics | 525 |
| II. Studies on the Immunopathogenesis of Type 1 Diabetes | 526 |
| III. Cellular Immune Reactions Against Pancreatic Islet Cells | 527 |
| C. NO as a Major Pathogenetic Factor in Immune-Mediated Diabetes | 528 |
| I. Cellular Sources of β -Cell-Damaging NO | 528 |
| 1. Macrophages | 528 |
| 2. Endothelial Cells | 529 |
| 3. β Cells | 529 |
| II. Primary Target Structures of NO in the β Cell | 530 |
| 1. Mitochondria | 530 |
| 2. Nuclear DNA | 530 |
| III. Pathways of NO-Induced β -Cell Death | 531 |
| 1. Mitochondrial Damage | 531 |
| 2. Apoptotic Pathway | 531 |
| 3. Poly(Adenosine Diphosphate–Ribose)Polymerase-Dependent Pathway | 532 |
| D. Open Issues | 533 |
| E. Strategies to Protect Islet Cells from NO-Induced Damage | 534 |
| I. Suppression of NO Formation | 534 |
| II. Improvement of β -Cell Defense Mechanisms | 535 |
| III. Inhibition of the PARP-Dependent Pathway | 536 |
| IV. Regulation of Th1/Th2 Balance in Islet Inflammation | 536 |
| F. Concluding Remarks | 537 |
| References | 538 |

CHAPTER 21

The Role of Nitric Oxide in Cardiac Ischaemia–Reperfusion

| | |
|--|-----|
| P.A. MACCARTHY and A.M. SHAH. With 2 Figures | 545 |
| A. Introduction | 545 |
| B. Consequences of Myocardial Ischaemia–Reperfusion | 546 |
| C. Interaction Between NO and ROS | 547 |
| D. Potential Ways in Which NO and ONOO [−] May Influence Myocardial Ischaemia–Reperfusion | 547 |
| I. Changes in Coronary Blood Flow and Vessel–Blood Cell Interactions | 550 |
| II. Direct Effects of NO and ONOO [−] on Myocardium | 550 |
| E. Experimental Studies | 551 |
| I. Post-Ischaemic Endothelial Dysfunction | 551 |
| II. Myocardial Function | 552 |

| | |
|--|-----|
| 1. NO as a Beneficial Agent | 552 |
| a) Post-Ischaemic Contractile Function | 552 |
| α . Buffer-Perfused Preparations | 556 |
| β . Blood/Neutrophil-Perfused Preparations | 557 |
| b) Myocardial Infarction | 557 |
| c) Reperfusion-Induced Arrhythmia | 558 |
| 2. NO as a Deleterious Agent | 559 |
| F. Reasons for Conflicting Experimental Results | 561 |
| G. NO and Ischaemic Preconditioning | 562 |
| H. Summary and Conclusions | 563 |
| References | 564 |

CHAPTER 22

Nitric Oxide and Atherosclerosis

| | |
|---|-----|
| H. BULT, K. E. MATHYS, and M.M. KOCKX | 571 |
| A. Introduction | 571 |
| B. Stages of Intimal Thickening and Atherosclerosis | 571 |
| I. The Physiological Intima: the Soil for Atherosclerosis | 571 |
| II. Successive Stages of Atherosclerosis | 572 |
| III. Accelerated Atherosclerosis | 572 |
| C. Pathogenic Mechanisms | 573 |
| I. The Initiation of Atherosclerosis | 573 |
| II. Remodeling of the Artery | 574 |
| III. Plaque Stability | 575 |
| D. Dysfunction of eNOS Signaling in Atherosclerosis | 575 |
| I. Impaired Relaxation in Isolated Arteries | 575 |
| II. In vivo Studies of the eNOS Defect in Atherosclerotic Arteries | 576 |
| III. The Systemic Nature of the Defective eNOS Signaling | 576 |
| E. Explanations for the Defective eNOS-Signaling Pathway | 577 |
| I. Endothelial Receptor Dysfunction | 577 |
| II. Expression of eNOS mRNA and Protein | 578 |
| III. THB Deficiency | 579 |
| IV. Arginine Availability | 579 |
| 1. Conduit Arteries with Atherosclerosis | 579 |
| 2. Conduit Arteries Without Overt Atherosclerosis | 580 |
| 3. Arterioles Without Overt Atherosclerosis | 580 |
| 4. Possible Explanations for the Arginine Paradox | 580 |
| V. Endogenous NOS Antagonists | 581 |
| VI. Negative Feedback by NO Derived from iNOS | 582 |
| VII. Superoxide Anion Inactivates NO | 582 |
| F. Expression of iNOS | 584 |
| I. iNOS Expression in Atherosclerosis | 584 |

| | |
|--|-----|
| II. Mechanical Injury and iNOS Expression | 585 |
| G. NO: a Radical with Anti-Atherogenic Properties | 585 |
| I. In Vitro Studies | 585 |
| 1. Interference with Oxidative Processes | 585 |
| 2. Maintenance of Endothelial Barrier Function | 587 |
| 3. Interference with Leukocyte Recruitment | 587 |
| 4. Antiproliferative Action of NO | 587 |
| 5. Antiplatelet Effects of NO | 588 |
| II. In Vivo Studies | 588 |
| 1. Inhibition of Experimental Atherosclerosis | 588 |
| 2. Inhibition of Intimal Thickening by NO | 590 |
| a) Neointima Formation after Balloon Denudation | 590 |
| b) Intimal Hyperplasia Due to Perivascular Manipulation | 591 |
| 3. Inhibition of Intimal Hyperplasia in Vein Grafts | 592 |
| 4. Inhibition of Intimal Hyperplasia Induced by Balloon Angioplasty | 592 |
| 5. Stimulation of Compensatory Remodeling | 592 |
| H. NO: a Radical Promoter of Atherosclerosis | 593 |
| I. Peroxynitrite Formation | 593 |
| II. LDL Oxidation | 594 |
| III. Oxidative Cell Injury | 594 |
| IV. NO and Apoptosis | 595 |
| 1. NO as an Inhibitor of Apoptosis in the Normal Arterial Wall | 595 |
| 2. NO as an Inducer of Apoptosis | 596 |
| a) PARP- and NO-Induced DNA Repair and Apoptosis | 596 |
| b) p53/p21 and NO-Induced DNA Repair and Apoptosis | 596 |
| 3. NO, Apoptosis and Plaque Stability | 597 |
| V. Matrix Breakdown | 598 |
| I. Summary | 598 |
| References | 599 |

CHAPTER 23

Nitric Oxide in Brain Ischemia/Reperfusion Injury

| | |
|---|-----|
| M. SASAKI, T.M. DAWSON, and V.L. DAWSON. With 2 Figures | 619 |
| A. Introduction | 619 |
| B. Neuronal NOS | 619 |
| C. Endothelial NOS | 623 |
| D. Immunologic NOS | 626 |
| E. The Role of NO in Focal Ischemic Brain Damage | 627 |

| | |
|------------------------|-----|
| F. Targets of NO | 629 |
| G. Summary | 631 |
| References | 631 |

CHAPTER 24

Therapeutic Potential of Nitric Oxide Synthase Gene Manipulation

| | |
|--|-----|
| H.E. VON DER LEYEN and V.J. DZAU. With 1 Figure | 639 |
| A. General Principles of Gene Therapy | 639 |
| B. Gain of Function | 640 |
| I. Overexpression of the NOS Gene | 640 |
| 1. Overexpression of Endothelial Constitutive NOS | 641 |
| 2. Overexpression of Inducible NOS | 644 |
| C. Loss of Function | 646 |
| I. Inhibition of NOS by Antisense Technology | 646 |
| D. Transgenic Animals with Disrupted NOS Gene | 647 |
| E. Potential Therapeutic Applications of NOS Gene Transfer | 649 |
| References | 649 |
| Subject Index | 655 |